Acquired BCL2 variants associated with venetoclax resistance in acute myeloid leukemia
Details
Publication Year 2025-01-14,Volume 9,Issue #1,Page 127-131
Journal Title
Blood Advances
Abstract
We report and characterize three venetoclax-resistant BCL2 variants arising during venetoclax/azacitidine therapy in acute myeloid leukemia (AML). Our results indicate the potential for on-target venetoclax resistance in patients with AML at relapse.
Publisher
ASH
Research Division(s)
Blood Cells And Blood Cancer; Structural Biology; Blood Cells and Blood Cancer
PubMed ID
39374584
Open Access at Publisher's Site
https://doi.org/10.1182/bloodadvances.2024014446
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-10-09 01:19:10
Last Modified: 2026-03-16 03:26:25
An error has occurred. This application may no longer respond until reloaded. Reload 🗙